The company held the 2017 Board of Directors and the Board of Supervisors
Release time:
2020-08-14
Company Held 2017 Board of Directors and Board of Supervisors
to Review and Pass the Annual Work Report and Other Relevant Proposals
News 4# November 20 , Chairman of the Group Company Jiang Xiaomeng presided over the 3 Meeting of the 10th Board of Directors of the Company, deliberated and passed 2017 Board of Directors Work Report, 2017 General Manager Work Report and other 15 proposals and reports.
General Manager's report pointed out that in 2017 , the company focused on the general work policy of "grasping trends, precise development, strengthening standards, improving quality, improving management, and enhancing efficiency", and grasped the optimization of economic structure and industry. Opportunities brought by upgrading, accelerate innovation and development, deepen management integration, continuously improve management level, improve enterprise operation efficiency, and strengthen marketing expansion, we have steadily promoted the growth of product sales, achieved remarkable results in technological innovation and technological transformation, continuously improved the financial structure, and further strengthened the core competitiveness of enterprises. In the whole year, the company realized operating income of 28.27 .8 billion yuan, up 18.81% year on year, and realized net profit attributable to owners of the parent company of 34849.43 yuan, up 22.18% year on year, reaching a new record high. Earnings per share of 1.01 yuan, achieving the best operating performance in the development process of peak 60 years; the total assets at the end of the year were 41.76 billion yuan, up 4.53 year on year; The net assets attributable to the owner of the parent company at the end of the year were 26.27 .4 billion yuan, up 10.13 year on year.
In 2017 , with the in-depth implementation of the national "the belt and road initiative" initiative, the off-peak production of cement has been promoted in an all-round way, the environmental protection supervision of the industry has been further improved, the supervision of energy conservation and consumption reduction has been tightened, the merger and reorganization has been deepened, the awareness of industry self-discipline has been continuously enhanced, and the supply-side structural reform of the cement industry has achieved initial results. The national cement production remained basically stable, but the price of cement products increased significantly year-on-year, and the profitability of the industry increased significantly. The company's cement business segment seizes regional development opportunities, in-depth implementation of cost leadership strategy, through technological transformation, organizational optimization and information management, cement production costs have been effectively controlled. Daye Jianfeng organized production through reasonable arrangements, actively explored key engineering projects, seized the civilian market, timely adjusted the credit mechanism, and effectively encouraged the sales team, and achieved good business performance; Yunnan Jianfeng seized strategic opportunities and developed through multiple channels Key projects continue to expand regional market sales share, while actively responding to the self-discipline of the cement industry in southwest Yunnan, continue to promote brand building, and further enhance corporate influence, achieved the best performance since the production.
In 2017 , the pharmaceutical industry achieved double-digit growth in revenue and profits. With the further improvement of living standards, the improvement of medical insurance and medical reform policies, the increase of the aging population and the liberalization of the two-child policy, the development prospects of the pharmaceutical industry for a long period of time in the future are still optimistic. During the reporting period, Jianfeng Pharmaceutical actively implemented the strategic layout according to the company's overall development plan, and made new breakthroughs in project cooperation. Peak Pharmaceuticals completed the first phase of its investment in Beihui Bio, holding a stake of 20% . The introduction of Shanghai Yien's anti-tumor compound patent technology, joint venture to form a peak Yien, focusing on the research and development of new anti-tumor drugs. 2018 1 , peak pharmaceutical investment in Shanghai North Carolina, will further strengthen the research and development of intermediates, API and base construction. These measures have further improved the company's pharmaceutical business industry chain, further improved its new drug research and development capabilities, and further enhanced the core competitiveness of the pharmaceutical sector. Peak Pharmaceuticals also responded to changes in the pharmaceutical market by strengthening market segment management, adjusting marketing models in a timely manner, enhancing the vitality of the marketing team, and strengthening marketing efforts, resulting in faster growth in industrial sales. In addition, the new anti-tumor drug DPT (deoxypodophyllotoxin) has completed the preparation of phase I clinical trial plan and obtained the ethical approval from the clinical team leader unit, making preparations for the entry of phase I clinical trial cases.
In addition, Tianjin Jianfeng actively explored the international market to ensure stable growth in sales revenue. Jianfeng Health has made great efforts to develop the market of Chinese herbal pieces by strengthening investment promotion, innovating the network sales mode, creating regional store terminal models, and achieving a large increase in business income. While stabilizing the existing market, Jianfeng Cable Company has successfully developed central plastic tube large logarithmic cable products through the transformation of existing equipment according to customer needs.; Jianfeng International Trade seized the opportunity of logistics industry development, reached a long-term cooperation agreement with Shanghai Anneng Logistics, and invested in a new logistics warehouse (e-commerce logistics park), which will become the new profit growth point of Jianfeng International Trade
. During the reporting period, the company deeply implemented management integration, comprehensively carried out "three reductions and three improvements" activities, continuously promoted organizational optimization, improved enterprise operation efficiency, enhanced enterprise internal vitality, and ensured further healthy and ensured the company's further stable development. On the day of
, the company also held the 72nd meeting of the 9th board of supervisors, deliberating and passing proposals and reports such as the company's 2017 annual board of supervisors work report and 2017 annual financial final accounts report. (Zhou Hengbin)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31